RecruitingNCT07122674
18F-Pentixafor PET in Hematologic Malignancies
Prospective Clinical Study of 18F-Pentixafor PET Imaging in Hematologic Malignancies
Sponsor
First Affiliated Hospital of Zhejiang University
Enrollment
100 participants
Start Date
Jul 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria5
- Age of 18-80 years old, both sexes, with behavioral capacity;
- patients with suspected or confirmed hematological malignancies;
- 18F-FDG PET or other imaging examinations should be performed according to the treatment plan;
- For suspected patients, biopsy or needle biopsy is expected to obtain pathological results;
- Can provide informed consent, can understand and comply with the requirements of the study.
Exclusion Criteria5
- pregnant and lactating women;
- patients with fear or radiophobia, or with mental disorder or primary affective disorder;
- received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv;
- received investigational drugs or devices of uncertain efficacy or safety within 1 month;
- Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG18F-Pentixafor
Patients with hematological malignancies receive 55 MBq/kg of 18F-Pentixafor intravenously followed by PET/CT or PET/MR after 60min of injection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07122674
Related Trials
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT0463455278 locations
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology
NCT053065091 location
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
NCT072206164 locations
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
NCT022695927 locations
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
NCT066526336 locations